Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2013 on Wednesday, February 26, 2014, After Close of

 Nektar to Announce Financial Results for the Fourth Quarter and Year-End of
  2013 on Wednesday, February 26, 2014, After Close of U.S.-Based Financial

PR Newswire

SAN FRANCISCO, Feb. 19, 2014

SAN FRANCISCO, Feb. 19, 2014 /PRNewswire/ --Nektar Therapeutics (Nasdaq:
NKTR) will announce its financial results for the fourth quarter and
year-ended December 31, 2013 on Wednesday, February 26, 2014, after the close
of U.S.-based financial markets. Howard Robin, president and chief executive
officer, will host a conference call to review the results beginning at 5:00
p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).

The press release and a live audio-only Webcast of the conference call can be
accessed through a link that is posted on the home page and Investor Relations
section of the Nektar website: The web broadcast of the
conference call will be available for replay through Monday, March 31, 2014.

 To access the conference call, follow these instructions:
 Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international)
 Passcode: 72309374 (Nektar Therapeutics is the host)

In the event that any non-GAAP financial measure is discussed on the
conference call that is not described in the press release, or explained on
the conference call, related information will be made available on the
Investor Relations page at the Nektar website as soon as practical after the
conclusion of the conference call.

About Nektar
Nektar Therapeutics (NASDAQ: NKTR) is a biopharmaceutical company developing
novel therapeutics based on its PEGylation and advanced polymer conjugation
technology platforms. Nektar has a robust R&D pipeline of potentially
high-value therapeutics in oncology, pain and other therapeutic areas. In the
area of pain, Nektar has an exclusive worldwide license agreement with
AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which
has been filed for regulatory approvals in the U.S., Europe and Canada as a
once- daily, oral tablet for the treatment of opioid-induced constipation.
This agreement also includes NKTR-119, an earlier stage development program
that is a co-formulation of naloxegol and an opioid. NKTR-181, a novel
mu-opioid analgesic molecule for chronic pain conditions, has completed Phase
2 development in osteoarthritis patients with chronic knee pain. NKTR-171, a
new sodium channel blocker being developed as an oral therapy for the
treatment of peripheral neuropathic pain, is in Phase 1 clinical development.
In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3
clinical study (the BEACON study) for the treatment of metastatic breast
cancer and is also in Phase 2 studies for the treatment of ovarian,
colorectal, lung and brain cancers. In anti-infectives, Amikacin Inhale is in
Phase 3 studies conducted by Bayer Healthcare as an adjunctive treatment for
intubated and mechanically ventilated patients with Gram-negative pneumonia.
Additional development-stage products that leverage Nektar's proprietary
technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII
program, which is in Phase 3 clinical development for patients with hemophilia

Nektar's technology has enabled eight approved products in the U.S. or Europe
through partnerships with leading biopharmaceutical companies, including UCB's
Cimzia^® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS^® for
hepatitis C and Amgen's Neulasta^® for neutropenia.

Nektar is headquartered in San Francisco, California, with additional
operations in Huntsville, Alabama and Hyderabad, India. Further information
about the company and its drug development programs and capabilities may be
found online at

SOURCE Nektar Therapeutics

Contact: Jennifer Ruddock, 415-482-5585
Press spacebar to pause and continue. Press esc to stop.